Lisanti Capital Growth’s LENZ Therapeutics LENZ Stock Holding History

Lisanti Capital Growth’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-87,753	Closed	-$4.09M	–	142
2025 Q3	$4.09M	Buy	87,753 +51,568	+143%	+$1.9M	1%	51
2025 Q2	$1.06M	Buy	36,185 +10,520	+41%	+$286K	0.29%	93
2025 Q1	$660K	Buy	+25,665	New	+$632K	0.2%	103

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Lisanti Capital Growth's LENZ Position: Q4 2025 in Review

Lisanti Capital Growth sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 87,753 shares — an estimated $4.09M sold.

Lisanti Capital Growth first reported a position in LENZ in Q1 2025 and held it in 3 quarters. The position peaked at $4.09M in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

Lisanti Capital Growth reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
Lisanti Capital Growth sold 87,753 LENZ Therapeutics shares in Q4 2025, an estimated $4.09M.
Lisanti Capital Growth first reported a position in LENZ Therapeutics in Q1 2025 and held it in 3 quarters.
Lisanti Capital Growth's LENZ Therapeutics position peaked at $4.09M in Q3 2025.
160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Lisanti Capital Growth's 13F filing for Q4 2025, filed 9 Feb 2026.